An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Golvatinib (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 15 Nov 2013 Planned end date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 15 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jan 2013 New source identified and integrated (10728: United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top